MAPT and early-onset autosomal dominant Alzheimer disease: The results underscore the potential of (±)-1, (+)-1, and (−)-1 to inhibit tau phosphorylation and its detrimental effects, suggesting their potential as therapeutic agents for Alzheimer’s disease.